Authors: Jade Parker, Editor
The TAILORx study has demonstrated that most women with a specific early-stage breast cancer and midrange score on the Oncotype DX® test do not need chemotherapy after surgery. These findings will spare thousands of women from the harmful effects of chemotherapy. In this interview we speak with Andrew Paramore from Genomic Health (CA, USA) to discover insider details of the trial and what’s next for TAILORx.
If you would like to read the news surrounding TAILORx, click here.
Interested in discovering other key ASCO talks? Discover our highlights here.
Transcript:Restricted Content / Members Only